The FDA has extended its review of Novartis’ potential multiple sclerosis drug ofatumumab, pushing back a decision on the repurposed cancer drug until September this year. Ofatumumab could ...

levels in patients treated with Kesimpta (ofatumumab) remained stable, and there was no apparent association between decreased IgG levels and the risk of serious infections. The findings were ...